BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8466551)

  • 1. Effects of monoamine oxidase inhibitors on the acid metabolites of some trace amines and of dopamine in the rat striatum.
    Dyck LE; Durden DA; Boulton AA
    Biochem Pharmacol; 1993 Mar; 45(6):1317-22. PubMed ID: 8466551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugation of phenylacetic acid and m- and p-hydroxyphenylacetic acids in the rat striatum.
    Dyck LE; Durden DA; Boulton AA
    Life Sci; 1993; 53(11):901-9. PubMed ID: 8366757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
    Kato T; Dong B; Ishii K; Kinemuchi H
    J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl.
    Hársing LG; Vizi ES
    Br J Pharmacol; 1984 Nov; 83(3):741-9. PubMed ID: 6439273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA; Juorio AV; Berry MD; Zhu MY
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
    Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
    Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
    Ilani T; Lamensdorf I; Finberg JP
    Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR; Abercrombie ED
    J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
    Sivam SP
    Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesion-induced reductions in trace amine accumulation: dependence on MAO inhibitor pretreatment.
    Nguyen TV; Juorio AV; Greenshaw AJ
    Brain Res Bull; 1989 Feb; 22(2):197-200. PubMed ID: 2495844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
    Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
    J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of type A and B monoamine oxidase selective inhibition by Ro 41-1049 and Ro 19-6327 on dopamine outflow in rat kidney slices.
    Pestana M; Soares-da-Silva P
    Br J Pharmacol; 1994 Dec; 113(4):1269-74. PubMed ID: 7889283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine.
    Berry MD; Scarr E; Zhu MY; Paterson IA; Juorio AV
    Br J Pharmacol; 1994 Dec; 113(4):1159-66. PubMed ID: 7889269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat.
    Garrett MC; Soares-da-Silva P
    Neuropharmacology; 1990 Oct; 29(10):875-9. PubMed ID: 2123970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma.
    Hovevey-Sion D; Kopin IJ; Stull RW; Goldstein DS
    Neuropharmacology; 1989 Aug; 28(8):791-7. PubMed ID: 2506486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
    Tekes K; Tóthfalusi L; Gaál J; Magyar K
    Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.